MatriSys Bioscience

Executive Summary

MatriSys Bioscience is a clinical-stage biotechnology company pioneering a novel class of live biotherapeutic products (LBPs) derived from the human skin microbiome to treat chronic inflammatory skin diseases. The company's platform identifies and optimizes beneficial bacteria from healthy skin to restore homeostasis, targeting conditions such as atopic dermatitis and acne. Founded in 2016 and headquartered in San Diego, MatriSys is advancing a deep pipeline of topical LBPs. The company's lead candidate is in Phase 2 development for atopic dermatitis, with the potential to transform treatment paradigms by addressing the underlying microbiome imbalance rather than just symptoms. MatriSys remains privately held and has not disclosed total funding, but its innovative approach and the growing interest in microbiome therapeutics position it as a promising player in the dermatology space. Key near-term catalysts include Phase 2 data readout, potential Series B financing, and strategic partnerships to support further clinical development and commercial scale-up.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 topline data for lead candidate in atopic dermatitis35% success
• Q2 2027Series B financing to advance pipeline70% success
• Q3 2027Strategic partnership with dermatology-focused pharma company50% success